Overview

Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy

Status:
Active, not recruiting

Trial end date:
2023-09-26

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well eltrombopag olamine works in improving the recovery of platelet counts in older patients with Acute Myeloid Leukemia (AML) undergoing induction (the first treatment given for a disease) chemotherapy. Platelet counts recover more slowly in older patients, leading to risk of complications and the delay of post-remission therapy. Eltrombopag olamine may cause the body to make platelets after chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Case Comprehensive Cancer Center

Collaborator:

National Cancer Institute (NCI)